Invention Grant
- Patent Title: Inhibitors of beta-hydroxylase for treatment of cancer
-
Application No.: US14430101Application Date: 2013-09-20
-
Publication No.: US09771356B2Publication Date: 2017-09-26
- Inventor: Jack R. Wands , Suzanne De La Monte , Arihiro Aihara , Mark Jon Olsen , John-Michael Thomas
- Applicant: Rhode Island Hospital , Midwestern University
- Applicant Address: US RI Providence US IL Downers Grove
- Assignee: Rhode Island Hospital,Midwestern University
- Current Assignee: Rhode Island Hospital,Midwestern University
- Current Assignee Address: US RI Providence US IL Downers Grove
- Agency: Mintz Levin Cohn Ferris Glovsky and Popeo, P.C.
- Agent Ingrid A. Beattie
- International Application: PCT/US2013/061050 WO 20130920
- International Announcement: WO2014/047519 WO 20140327
- Main IPC: C07D307/26
- IPC: C07D307/26 ; C07D405/04 ; C07D417/04 ; C07D307/66 ; C07D307/32 ; C07D405/12 ; C07D409/04 ; C12Q1/26

Abstract:
The present invention relates to compounds which modulate (e.g., inhibit) the activity of beta-hydroxylase (e.g., Asparatyl (asparaginyl) β-hydroxylase (ASPH)), including novel 2-aryl-5-amino-3(2H)-furanone and 2-heteroaryl-5-amino-3(2H)-furanone compounds, pharmaceutical compositions thereof, methods for their synthesis, and methods of using these compounds to modulate the activity of ASPH in an a cell-free sample, a cell-based assay, and in a subject. Other aspects of the invention relate to use of the compounds disclosed herein to ameliorate or treat cell proliferation disorders.
Public/Granted literature
- US20150210677A1 Inhibitors of Beta-Hydroxylase for Treatment of Cancer Public/Granted day:2015-07-30
Information query